Myristic acid
CAS No. 544-63-8
Myristic acid ( —— )
Catalog No. M18773 CAS No. 544-63-8
Myristic Acid, a 14 carbon saturated fatty acid, is a rare molecule in cells and is a substrate of some fatty acid desaturases.
Purity : 98%
Size | Price / USD | Stock | Quantity |
500MG | 35 | In Stock |
|
1G | 42 | In Stock |
|
Biological Information
-
Product NameMyristic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionMyristic Acid, a 14 carbon saturated fatty acid, is a rare molecule in cells and is a substrate of some fatty acid desaturases.
-
DescriptionMyristic Acid, a 14 carbon saturated fatty acid, is a rare molecule in cells and is a substrate of some fatty acid desaturases. This compound has the ability to acylate proteins by covalently binding to the N-terminal glycine residues, in a process called N-terminal myristoylation. Myristoylation of substrate proteins by this fatty acid has the potential to activate and mediate many physiological pathways. Furthermore, saturated fatty acids have been reported to be essential for biological activities of lipopolysaccharides and have demonstrated the ability to induce expression of COX-2 and NFκB (nuclear factor κB) activation.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number544-63-8
-
Formula Weight228.38
-
Molecular FormulaC14H28O2
-
Purity98%
-
SolubilityDMSO : ≥ 250 mg/mL; 1094.71 mM
-
SMILESO=C(O)CCCCCCCCCCCCC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Evodol
Evodol may as an anti-inflammatory agent or lead compound, it shows inhibitory activity on nitric oxide (NO) production in lipopolysaccharide -activated RAW264.7 macrophages.
-
DL -34-Dihydroxymand...
34-Dihydroxymandelic acid is a minor metabolite of norepinephrine in humans. Patients with neuroblastoma experience elevated levels of 34-Dihydroxymandelic acid.
-
FIDAS-5
FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.